653 related articles for article (PubMed ID: 15711274)
1. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
2. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters.
Mock S; Leapman M; Stock RG; Hall SJ; Stone NN
J Urol; 2013 Nov; 190(5):1805-10. PubMed ID: 23669568
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
4. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
Stone NN; Stock RG
Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
[TBL] [Abstract][Full Text] [Related]
5. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT
J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718
[TBL] [Abstract][Full Text] [Related]
6. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
7. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
[TBL] [Abstract][Full Text] [Related]
8. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
9. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
[TBL] [Abstract][Full Text] [Related]
12. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate.
Moran BJ; Stutz MA; Gurel MH
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):392-6. PubMed ID: 15145153
[TBL] [Abstract][Full Text] [Related]
13. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
14. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.
Sarosdy MF
Cancer; 2004 Aug; 101(4):754-60. PubMed ID: 15305406
[TBL] [Abstract][Full Text] [Related]
15. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
[TBL] [Abstract][Full Text] [Related]
16. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
Stone NN; Marshall DT; Stone JJ; Cesaretti JA; Stock RG
J Urol; 2010 Feb; 183(2):634-9. PubMed ID: 20018308
[TBL] [Abstract][Full Text] [Related]
17. Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer.
Luo HL; Fang FM; Chuang YC; Chiang PH
BJU Int; 2009 Dec; 104(11):1620-3. PubMed ID: 19624535
[TBL] [Abstract][Full Text] [Related]
18. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
19. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
20. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
